Tom Le Voyer
Inserm(FR)Université Paris Cité(FR)Hospital for Sick Children(CA)Saint Louis University Hospital(US)Hospital for Sick Children Pediatric Center(US)Assistance Publique – Hôpitaux de Paris(FR)SickKids Foundation(CA)Hôpital Saint-Louis(FR)Pediatrics and Genetics(US)Human Genetic of Infectious Diseases(FR)Institut des Maladies Génétiques Imagine(FR)Rockefeller University(US)
Publications by Year
Research Areas
Immunodeficiency and Autoimmune Disorders, COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Immune Cell Function and Interaction, Diabetes and associated disorders
Most-Cited Works
- → Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths(2021)617 cited
- → Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1(2021)300 cited
- → Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine(2021)228 cited
- → The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies(2022)183 cited
- → Autoantibodies against type I IFNs in patients with critical influenza pneumonia(2022)125 cited
- → Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients(2023)104 cited